HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Lupin's Brazilian subsidiary acquires rights to nine brands from Bausch Health
Nov-28-2022

Lupin’s wholly owned subsidiary in Brazil, Medquimica Industria Farmaceutica (MedQuimica), has signed a definitive agreement to acquire all rights to nine medicines from BL Industria Otica, a subsidiary of Bausch Health Companies Inc. As part of the transaction, MedQuimica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease. This move reinforces the company’s commitment to making healthcare solutions accessible to all patients.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

  RELATED NEWS >>